Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...
The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs such as semaglutide (Ozempic or Wegovy), has been censured by the UK’s Prescription Medicines Code of Practice ...
NORTH OLMSTED, Ohio — Faucet and home fixture manufacturer Moen will close it's North Olmsted headquarters by sometime next year, its parent company confirmed Wednesday. In a statement to 3News ...
Despite having "fully embraced" hybrid work, Pemco says it will maintain its headquarters building overlooking Lake Union. There was concern among Seattle boosters two and a half years ago when ...
A new study found that patients taking GLP-1s to treat type 2 diabetes have a lower risk of developing Alzheimer’s disease, potentially opening the door … ...
On Tuesday, BofA Securities expressed continued confidence in Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), maintaining a Buy rating and a price target of DKK1,075.00. The endorsement comes amidst ...
Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback